Connect with us

General News

No Association of Cannabis with Reducing Opioid Epidemic, Study Suggests

Published

on

opioi addiction

A study from 2014 suggested that states that allowed marijuana for medical purposes had a comparatively lower number of deaths resulting from opioid addiction. The recent evidence suggests otherwise. Scientists from Stanford say that they have found no association between cannabis accessibility and alleviation in opioid addiction. Scientists from Stanford University School of Medicine conducted the research.

The recent study is in contradiction with the study conducted in 2014. According to the latter, there was a decrease in the overdose of opioid in the regions who legalized marijuana for recreational purposes in comparison to the states who did not legalize it.

The new findings suggest the opposite

The scientists from Stanford reevaluated the study after the number of the states legalizing cannabis for medical purposes increased. They found no proof of any association of deaths resulting from opioid overdose and accessibility of cannabis for medical purposes.

The new study got published on June 10. It appears online in the Proceedings of the National Academy of Sciences.
California became the first US state to have legalized cannabis in 1996. In 2013, 13 states joined the league. Now, 47 US states allow the use of medical marijuana.

Scientists employed the same method of study as the previous one

In the new research, scientists from Stanford employed the same method from the previous study to recognize the association of medical cannabis and deaths occurring due to opioid overdosage. The researchers reevaluated the statistics from the previous research. However, they found deviated results from the years following 2014 up to 2017. This deviation showed a fault in the previous hypothesis. On the contrary, they found that states with legal, medical cannabis showed higher death rates because of opioid abuse.

After the 2014 research got published, advocating parties for medical cannabis and some officials took the findings to convey the meaning that the access of legal cannabis will serve as replacement therapy for people addicted to opioids. The researchers at Stanford, however, did not find any association of this kind. The restriction levels did not intervene, as well.

There were several aspects to the findings from the previous study in 2014

The change in laws in various states did not guarantee any decline in opioid abuse whatsoever. In addition to that, only 2.5 percent of Americans use cannabis for medical purposes. This amount is logically enough to explain that the legalization was not sufficient to decline mortality rates due to opioid usage. There is a need to rightly evaluate the statistical ratio between the two to adequately study the relation.

Moreover, the political atmosphere concerning the issue was different in 2014 as compared to now, and it could significantly affect the restriction levels of cannabis. The states with legalized medical cannabis were financially more stable and had more liberal viewpoints on political grounds as compared to the states with no legalization. The US states legalizing cannabis earlier also punish lesser amount of people for using it. After their release, they might try to overdose on the drug.

There is a need to find its potential benefits and harms on a deeper level, without which its association with other drugs is not well possible enough to comprehend on a more profound level. There is a need to intricately evaluate the policies of states on the use of cannabis for medical purposes.

Scientists from the Network for Public Health Law and New York University supported the research. National Institutes of Health and the U.S. Department of Veterans Affairs financially aided the study. Stanford’s Department of Psychiatry and Behavioral Sciences was also involved in the research.

Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Cannabis

What Does 2020 Hold For Marijuana Stocks?

mm

Published

on

marijuana stocks

The relaxation of marijuana-related laws across the USA has certainly increased investment prospects in marijuana stocks. With rising global interest in the market, the future of marijuana stocks holds promising results for investors.

This move has opened new opportunities for the venture portfolios of stakeholders in the market.  If things move in the right direction, one can expect exceptional returns along with improvements in economic indicators.

Is 2020 a year of recession?

The year 2020 has seen unbridled economic uncertainty and changing trends in the stock market so far. After a slight recovery from the market crash that began in February, speculations of further bearish market trends have left investors, skeptical.

For some stakeholders, classifying this year as a period of recession is an early ruling. The National Bureau of Economic Research, however, has a contradicting verdict. It categorizes 2020 as a recessive year due to the unconventional drop in unemployment and production it triggered globally.

It is not surprising to see how the stock market is striving hard to recover from the recent unexpected blows. Investment opportunities offered by marijuana stocks can certainly help economies tolerate the effects of this partial recession. Many hope this year sees a shorter dip of growth as compared to the previous episodes of contraction.

CNBC

Did marijuana stocks perform well in 2020?

Despite the pandemic, the trend in the growth of marijuana stocks has been encouraging in the past few months. This trend has made marijuana stocks a safe haven for investors who are hungry for higher returns on investments.

Part of this growth in marijuana stocks can be associated with the pandemic itself. People following SOPS are turning towards marijuana usage for recreational purposes, causing a spike in consumption.

The recent policy by 11 states permitting recreational marijuana usage is a big move that has spiked marijuana stock prices. In addition, 33 other states that permitted medicinal usage, has opened new windows for marijuana-related investments.

This decriminalization of marijuana has also become a new and attractive source of tax revenue for the government. According to Forbes, the state of Washington has generated around $319 million in cannabis tax revenue, while California and Colorado produced $ 300 million and $266 million respectively.

With the increasing burden of social benefits, these tax revenues may spike federal interest. This factor has also piqued the interest of stakeholders, as the marijuana industry has not only survived well but outperformed various sectors in this pandemic permeated year, making it a big source for job generation and tax revenues for the government.

This has been a much welcome change for ancillary companies like KushCo holdings Inc. The company has seen a massive growth of 130% since March of 2020, as compared to the previous losses of 45% in revenues. The company now stands on the hot list for investors, who are eyeing it as a profitable future investment.

Other companies like OrganiGram Holdings, Aurora Cannabis, Aphria, etc. are also making it to that list successfully. This can be associated with increased demands from countries like Poland, Germany, and Canada, which now allow recreational marijuana use.

Another less discussed factor that may probe spikes in marijuana stock prices is an increased diversion of the general public towards alternate medicine. There are speculations for the CBD market to grow to $1.3 billion by 2022 from a $390 million in 2018 according to New Frontier Data.

With big chain stores like Kroger, Wholefoods, and American Eagle showing interest in selling an extended range of CBD products, investors can expect the market for marijuana and its related derivatives to see a positive trend in growth rate, providing profitable investment prospective.

All in all, it can be deduced that the marijuana industry has a lot of potentials not only in the United States but also globally. This makes it a safe investment for stakeholders considering the market trends so far.

Continue Reading

General News

Study: Cannabis Terpene Treatment For COVID-19

Published

on

Cannabis Terpene NT-VRL

A recent Israeli study has found a possible treatment for COVID-19 complications in cannabis. The chemical CBD (cannabidiol) has been studied in a combination with a cannabis terpene (NT-VRL). This CBD is one of the key ingredients in cannabis sativa. Meanwhile, the cannabis terpene NT-VRL (patent of Ebyna) is an aromatic chemical from the flowers of the plant. When administered in combination, there has been a noticeable positive effect on ‘cytokine storm’, a feared complication of COVID-19.

Cytokine storm is a dangerous reaction to COVID-19 by the body’s immune system

The term ‘cytokine storm’ refers to a chain reaction of immune cells, causing increasing levels of inflammation. Because the body is responding the the coronavirus infecting the patient, it secretes small proteins called ‘cytokines’. Usually, these have small but important roles in helping kill off the virus by creating inflammation and fever. However, when this reaction goes unchecked, it can be deadly if untreated. The patient would undergo very high levels of fever, fatigue, inflammation and in worst-cases, respiratory failure.

This is why the recent discovery that COVID-19 can lead to cytokine storm was so shocking. It meant that even young, healthy people with strong immune systems would be susceptible to potential deaths from this disease. Furthermore, the most widely-used drug of choice for treating this, dexamethasone, is undergoing global shortage.

The company, Ebyna, had patented the cannabis terpene, NT-VRL

The study was a collaboration between Ebyna, the terpene company, and Cannasoul, a cannabis research entity. Thus, Ebyna and Cannasoul’s joint venture led to the formation of an inhalant drug. This contained NT-VRL, to be administered with or without CBD. The aim of the study was to investigate the effects they had on treating cytokine storm from COVID-19.

Long just dismissed as simply useful in the flavor/smell of cannabis products, terpenes were shown to be very effective in this case. When combined with the CBD, which has also been shown to have positive health effects, it was remarkable. The combined therapy of both CBD and NT-VRL significantly improved symptoms of cytokine storm from COVID-19.

“This type of delivery [inhaled, rather than ingested] method is a game-changer enabling us to achieve therapeutic qualities from these unique phytochemicals like never before,” said Nadav Eya, the CEO of Ebyna. He was referring to the unexpected efficacy of the NT-VRL therapy in this COVID-19 complication.

Other studies confirm Ebyna-Cannasoul’s findings

Outside of Israel, several studies report similar findings. More and more researchers are turning to cannabis byproducts to battle the COVID-19 pandemic.

Igor and Olga Kovalchuck, researchers from Canada, were both developing a new strain of cannabis. Their aim was to extract anti-cancer drugs from it. However, the new COVID-19 pandemic caused them to shift focus towards combating the coronavirus. Their strain is hoped to be able to produce a drug that could reduce the communicability of SARS-CoV2. It would do so by restricting the ACE-2 receptors in the body.

All in all, Ebyna and Cannasoul’s NT-VRL terpene may just be revolutionary. The existence of terpene as an anti-cytokine storm drug is still debatable, and more research is still required. However, their study and that of corroborators have shown that cannabis is even more useful a plant than we had ever suspected. For more news and updates on the state of the CBD-terpene therapy, stay tuned. In the meanwhile, check out other recent studies on CBD here.

Continue Reading

General News

Endocanna Health Aims To Increase Genetic Risk Awareness For COVID-19

Published

on

COVID-19

This pandemic is practically unprecedented in terms of how mysterious its risk factors are. While the mode of transmission is known, the exact factors that make a person susceptible to severe complications aren’t. Experts all agree that COVID-19 may either pass the infected with no symptoms, cause mild respiratory effects or in worst-cases deaths.

However, what still remains unclear is who is vulnerable and why. That’s why Endocanna Health, a cannabinoid DNA-research company based in California, has stepped up. They are offering a free DNA test for genetic factors in their consumers. This test is meant to scan for known genetic markers that could lead to susceptibility. While the gesture is generous, it must be cautioned such a test is not meant to be a reliable tool to assess this.

DNA research works by looking for known markers

The aim of Endocanna Health’s test is to examine possible vulnerable genes. Such genes could make a person’s immune system weaker to infection, or allow them to develop worse symptoms.

However, if you’re wondering why you haven’t been prescribed this test before, there’s a reason. Most healthcare providers and experts don’t rely on such tests because they only indicate correlation. There is no way to prove the causation. What that means, simply, is that certain genes can make COVID-19 more severe, not always. Factors like age, diet, health conditions and mental health are important too, though.

Endocanna Health’s research is most notable for its work on the human endocannabinoid system. This system includes the way certain cannabinoid neurotransmitters work to regulate mood, sensation, memory, metabolism and immunity.

The system was discovered by scientists investigating the effects of THC in marijuana on the body. While we did just mention immunity back there, it must be kept in mind that this is only part of it (more on that later).

The company’s Chief Science Officer, Dr Chris Spooner, recently claimed that the work they were doing would be useful for understanding the immune system. He mentioned the presence of cannabinoid receptors in the immune cells, that affected the strength of immune response to COVID-19. While the role of cannabinoids on the cells is clear, the message behind the aims should be scrutinized.

Your genes are not the most important factor in beating COVID-19

If Endocanna Health’s aim is to combat COVID-19, then that’s commendable. But if they think that it will significantly contribute to flattening the curve, their hopes are a tad misplaced. Major health experts, from Dr Anthony Fauci to the WHO, all assert that the number one rule to follow is to stay healthy and socially distance. If you’re worried about COVID-19, or another similar disease, then eat healthy, sleep well and stay home. DNA tests can be helpful, truly, in the case of congenital disease (think cystic fibrosis or hemophilia). But to cause misinformation about them is deliberately harmful. Let’s look at the real unsung heroes in the body’s immune system.

To fight infection, circulating white blood cells (called leucocytes) detect and attack germs. They also signal the release of chemicals like prostaglandins to create inflammation and fever, which can be beneficial.

Other cells, like mast cells, help signal the response to rest of the system. Then, from the antigens of the germs, ‘B-Cells’ create antibodies. Antibodies are basically drugs to kill off any other germs left, from bacteria to coronaviruses. This whole process is wonderfully self-regulated. And knowing your genes will just make you more paranoid than actually help, it seems.

Continue Reading

Trending

error: Content is protected !!